Akums Drugs & Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,342 Cr +31.8% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
AD

Akums Drugs & Pharmaceuticals Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,024Cr
+0.5% YoY
−3% QoQ
Net profit
₹65Cr
+6.6% YoY
−56.7% QoQ
Margin
13%
0 pp YoY
+4 pp QoQ
Price₹750
Market cap₹11.4K Cr
P/E37.5

The short version

CDMO Business: CDMO Business: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.

From Akums Drugs & Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • CDMO Business:
  • Expected mid-single-digit topline growth in FY26 due to continued soft API prices.
  • Rs. 300 crore annual revenue anticipated from the new EU CDMO contract starting April 2027, with full ramp-up possibly taking 2-3 years.
  • Five-year target of $100 million in exports, scaling up from the current $15 million in formulation exports.
  • Domestic Branded Formulations:
  • Expected to track IPM growth, with subdued 3-4% growth in Q1 seen as a one-off.
  • Anticipated better performance in subsequent quarters, maintaining overall yearly guidance.
  • International Branded Formulations:
  • High-teen growth expected for the full year despite weaker current quarter.
  • API Business:
  • Continued focus on global expansion (Europe, Africa, LATAM) and improved API pricing.
  • Single-digit growth expected amidst pricing pressure domestically.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.
  • Current ongoing capex projects include expansion at Baddi plant and utilization ramp-up at Haridwar facility.
  • Strategic inorganic investments focus on acquiring dosage form capabilities either within India or abroad to gain access to new markets and expand product portfolios.
  • Consideration for acquisitions targeting companies with strong R&D, quality manufacturing, and global market access, aiming to launch new products quickly.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Akums Drugs & Pharmaceuticals has recently received a significant contract worth Rs. 300 crores linked to European markets.
  • They have other ongoing contracts of smaller values in progress.
  • Current export business run rate stands at Rs. 150 crores.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Akums Drugs & Pharmaceuticals Ltd Q1 FY26 results — key figures

Akums Drugs & Pharmaceuticals Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue1,0241,019+0.5%1,056-3%
Operating profit (EBITDA)129128+0.8%94+37.2%
Operating margin13%13%0 pp9%+4 pp
Profit before tax9687+10.3%75+28%
Net profit (PAT)6561+6.6%150-56.7%
EPS (₹)4.034.08-1.2%9.38-57%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Akums Drugs & Pharmaceuticals Ltd Q1 FY26 results?

CDMO Business: CDMO Business: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.

What is Akums Drugs & Pharmaceuticals Ltd share price analysis?

Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.

Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?

Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.

Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.